Positive cytoplasmic CAV1 conferred over 2-fold risk for contralateral breast cancer HRadj 2.63 (95% CI 1.36–5.10), while stromal CAV1 conferred nearly 2-fold risk for locoregional recurrence HRadj 1.88 (95% CI 1.09–3.24, Fig. 3; Supplementary Table 3). Here, CAV1 is linked to breast carcinoma.